-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compiler: Fan Dongdong
A few days ago, news showed that Novartis may divest its generic drug division Sandoz (Sandoz) in the process of promoting the divestiture of its generic drugs and consumer businesses across the industry
If it succeeds in the end, the acquisition amount of more than 20 billion U.
According to reports, Thomas and Andreas of the Struengmann family sold the generic drug company Hexal to Novartis in 2005, and the company has also become part of Sandoz
It is not uncommon for large pharmaceutical companies to adjust their generic drug business
Without the approval of the US FTC, Sandoz terminates the transaction of US$1 billion worth of pharmaceutical assets
In 2018, when Novartis revealed a plan to grant Sandoz more autonomy, similar to the divestiture of other pharmaceutical giants, this move was designed to allow them to focus on high-risk, high-return drug development businesses
Like many other generic drug manufacturers, Sandoz has been struggling to cope with falling prices in the US market
Reference source:
1.
2.
